Compared with placebo , rosuvastatin treatment significantly reduced the incidence of periprocedural myocardial infarction ( PMI ) and levels of cardiac troponin I ( cTnI ) associated with decreased relative expression of serum miR-155 , levels of inflammatory cytokines ( INF - , TNF - , and IL-6 ) , increased SHIP-1 expression and CD4 ( + ) FoxP3 ( + ) Treg percentage values ( P < 0.05 ) .